IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Mirati Therapeutics Inc

CUSIP: 60449T107 | 1 institutional holders

Quarters

Q4 2014
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q4 2014

Rhenman & Partners Asset Management AB45,388
0.0% of portfolio›$841
StyleTurnoverLocationFiled
Rhenman & Partners Asset Management AB
45,388$8410.0%CoreHighStockholm, Sweden2015-02-09